Short answer
Gossamer Bio, Inc. (GOSS) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $38M (up 189.1% year over year) with net income of −$48M.
Q3 2026 key financials · XBRL
- Revenue
- $38M
- +189.1% YoY · +316.0% QoQ
- Net income
- −$48M
- +0.3% YoY · −384.4% QoQ
- Operating margin
- 18.7%
- EPS (diluted)
- −$25.37
- −11981.0% YoY · −63325.0% QoQ
Source: XBRL data from the Gossamer Bio, Inc. (GOSS) Q3 2026 10-Q on SEC EDGAR. USD.
Gossamer Bio, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $38.4M, up $25.1M YoY from $13.3M, driven by $37.1M contract-liability release
- Operating margin 18.7% vs (369.4)% YoY, reflecting operating income $7.2M vs loss $49.1M
- Seralutinib largest development program, R&D expense $18.2M vs $45.5M YoY
- Cash, cash equivalents and marketable securities $51.2M at September 30, 2026, funding operations into Q1 2027
- Operating cash use $107.7M, August private placement provided $25.0M, NDA acceptance and capital needs remain key uncertainties
Risk Factors
- Regulatory risk: PROSERA missed its primary endpoint, potentially prompting FDA rejection, added studies, or narrower seralutinib labeling
- Filing risk: FDA may refuse NDA filing despite September 2026 submission and favorable Pre-NDA meeting interpretation
- Liquidity risk: Missed NDA Acceptance Milestone could eliminate approximately $125.0 million Second Closing proceeds by December 31, 2026
- Financing risk: Purchase Agreement restrictions may limit additional equity fundraising if the Second Closing fails
- Development risk: Additional FDA-required studies could delay approval and increase seralutinib development costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gossamer Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.